Section Arrow
CERS.NASDAQ
- Cerus Corp
Quotes are at least 15-min delayed:2025/02/01 11:52 EST
Last
 1.87
-0.11 (-5.56%)
Day High 
1.98 
Prev. Close
1.98 
1-M High
2.235 
Volume 
1.32M 
Bid
1.82
Ask
1.95
Day Low
1.845 
Open
1.97 
1-M Low
1.5 
Market Cap 
367.72M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.93 
20-SMA 1.79 
50-SMA 1.75 
52-W High 2.585 
52-W Low 1.375 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.11/-0.32
Enterprise Value
441.26M
Balance Sheet
Book Value Per Share
0.29
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
156.37M
Operating Revenue Per Share
0.83
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SENSSenseonics Holdings0.9608-0.1292-11.85%-- 
QSIQuantum-Si1.98+0.02+1.02%-- 
PACBPacific Biosciences of California1.54-0.06-3.75%-- 
MDTMedtronic plc90.82-1.17-1.27%28.13PE
ABTAbbott Laboratories127.93-0.88-0.68%39.2PE
Quotes are at least 15-min delayed:2025/02/01 11:52 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.